Glycididazole Sodium Combined with Radiochemotherapy for Locally Advanced Nasopharyngeal Carcinoma

Abstract

Background: To evaluate efficacy and side effects of glycididazole sodium (CMNa) combined with chemotherapy (cisplatin plus 5-FU/folic acid, PLF) and radiotherapy in treating patients with locally advanced nasopharyngeal carcinoma. Materials and Methods: Patients with Ⅲ~Ⅳ stage nasopharyngeal carcinoma (NPC),were randomly divided into treatment group (46 patients) and control group (45 patients). Both groups received radiotherapy concomitant with PLF chemotherapy. The treatment group at the same time cwas given CMNa (800 mg/m 2 before radiotherapy), by l h intravenous drip, three times a week. Results: When the dose of radiation was over 60 Gy, complete response rates of nasopharyngeal tumor and lymph node metastases in treatment group were significantly higher than in the control group (93.5% vs 77.8%; 89.1% vs 93.5%, p<0.05). Three months after radiotherapy, complete response rate of nasopharynx cancer and lymph node metastases in treatment group was both 97.8%, again higher than in the control group (84.4% and 82.2%) (p<0.05). In the treatment group, 1, 3, 5 year disease-free survival rates were 95.7%, 86.7% and 54.5%; and in control group, the corresponding disease-free survival rates were 93.3%, 66.2% and 38.6%, respectively, the difference being statistically significant (log-rank =5.887, p=0.015). One, 3, 5 year overall survival rates in two groups of patients were 97.8%, 93.5%, 70.4% and 95.5%, 88.07%, 48.4%, respectively, again with a statistically significant difference (log-rank=6.470, p=0.011). Acute toxicity and long-term radiotherapy related toxicity in the two groups did not differ (p>0.05). Conclusions: Glycididazole sodium could improve curative effects without increasing adverse reactions when treating paitents with locally advanced nasopharyngeal carcinoma.

Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

“…Although the acute adverse reaction was increased obviously in study group, late radiotherapy toxicity did not increase. For example, the grade 1-2 xerostomia was 40%, which was similar with Li (2014).…”

Clinical efficacy of radiotherapy combined with sodium glycididazole in the treatment of recurrent oesophageal carcinoma

“…Additionally, it is characterised by high safety and efficacy because it does not accumulate in the patient's body. Previous clinical studies have shown that the drug can greatly increase the sensitivity of cells in head and neck neoplasms and oesophageal carcinoma, and it has good short-term effects [16][17][18][19].…”

Correlation of hypoxia status with radiosensitizing effects of sodium glycididazole: A preclinical study

“…Preliminary study indicated that CMNa was able to improve short-term locoregional control and was well tolerated in patients with locoregionally advanced laryngeal cancer (12). The phase II randomized trial demonstrated that CMNa was able to improve curative effects without increasing adverse side effects when treating patients with locally advanced nasopharyngeal carcinoma (13).…”